September 2025 Quarterly Activities Report and Appendix 4C
| Stock | Noxopharm Ltd (NOX.ASX) |
|---|---|
| Release Time | 30 Oct 2025, 8:58 a.m. |
| Price Sensitive | Yes |
Noxopharm reports quarterly progress, secures funding
- New collaborations as Sofra interest continues
- SOF-SKN safe and well tolerated in HERACLES clinical trial
- US company announcement shows Sofra potential
Noxopharm Limited (ASX:NOX) has provided its Quarterly Activities Report and Appendix 4C for the period ending 30 September 2025. The company reported that interest in its Sofra technology platform continues to grow, with Noxopharm signing several collaboration agreements with Australian and international academic and research institutions. These collaborations aim to further demonstrate the versatility of the Sofra platform and generate data that could be valuable in the future. Noxopharm also announced initial results from a US company, Tezcat Biosciences, which has been evaluating the payload potential of Sofra oligonucleotides. The American company's preclinical studies have produced highly promising outcomes, demonstrating that Noxopharm's oligos can be successfully attached to Tezcat's delivery system to create a novel drug candidate with strong anti-inflammatory activity. In the HERACLES clinical trial, SOF-SKN was given to four cohorts, each with four participants receiving a single dose, and all dose levels were determined to be safe and well tolerated, with no clinically relevant issues found. This achievement represents a sustained effort from the company to leverage the Sofra platform and demonstrate its potential. Financially, Noxopharm had A$935k in cash as of 30 September 2025, and the company continues to explore options to secure additional capital, including a A$1.25m unsecured loan agreement with a company controlled by the Chairman. The company is also exploring the likelihood of short-term catalysts that may impact the timing and range of options to secure follow-on funding.
Noxopharm sees the development of SOF-SKN as just the first step in leveraging the Sofra platform to tackle much larger markets, with autoimmune diseases affecting approximately 780 million people worldwide. The company is continuing to find opportunities to build the Sofra pipeline and demonstrate the platform's potential in various diseases.